Cancers, Vol. 12, Pages 880: Downstream Effectors of ILK in Cisplatin-Resistant Ovarian Cancer

Cancers, Vol. 12, Pages 880: Downstream Effectors of ILK in Cisplatin-Resistant Ovarian Cancer Cancers doi: 10.3390/cancers12040880 Authors: Jeyshka M. Reyes-González Blanca I. Quiñones-Díaz Yasmarie Santana Perla M. Báez-Vega Daniel Soto Fatima Valiyeva María J. Marcos-Martínez Ricardo J. Fernández-de Fernández-de Thomas Pablo E. Vivas-Mejía Despite good responses to first-line treatment with platinum-based combination chemotherapy, most ovarian cancer patients will relapse and eventually develop platinum-resistant disease with poor prognosis. Although reports suggest that integrin-linked kinase (ILK) is a potential target for ovarian cancer treatment, identification of ILK downstream effectors has not been fully explored. The purpose of this study was to investigate the molecular and biological effects of targeting ILK in cisplatin-resistant ovarian cancer. Western blot analysis showed that phosphorylation levels of ILK were higher in cisplatin-resistant compared with cisplatin-sensitive ovarian cancer cells. Further immunohistochemical analysis of ovarian cancer patient samples showed a significant increase in phosphorylated ILK levels in the tumor tissue when compared to normal ovarian epithelium. Targeting ILK by small-interfering RNA (siRNA) treatment reduced cisplatin-resistant cell growth and invasion ability, and increased apoptosis. Differential gene expression analysis by RNA sequencing (RNA-Seq) upon ILK-siRNA transfection followed...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research